Drug Database
Back to search

Italy· 042306035

SEEBRI BREEZHALER

A glycopyrronium bromid product containing glicopirronio, registered in Italy by NOVARTIS EUROPHARM LTD, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.

Reimbursed in Italy (AIFA class A)ATC R03BB06

Checked against AIFA (Italy) on

Informational only — not a medical device.

SOURCE REGISTER · ITAIFA (Italy)normalisedSEEBRI BREEZHALERATCR03BB06REGISTER NO.042306035PACKS LISTED1CHECKEDSeptember 28, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about glicopirronioAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Glycopyrronium bromid is registered in 12 of 19 countries.

Countries holding a registration under ATC R03BB06 (glycopyrronium bromid), each read from that country’s own register.

  • This record: Italy, from AIFA (Italy)
  • 8 of them publish a price we can compare per daily dose
Search glycopyrronium bromid products by name

Glycopyrronium bromid · ATC R03BB06

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of glycopyrronium bromid costs, country by country.

Normalised to the WHO defined daily dose (44 mcg), the median price runs from $0.95 in Italy to $1.46 in Switzerland — a ×1.5 gap.

  • Italy: $0.95 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown
Open the full comparison — free accountDrug prices for market access

Glycopyrronium bromid · price per daily dose (44 mcg)

USD · FX 28 Sept 2026

  • CH Switzerland$1.46
  • IT Italy$0.95
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

AIFA (Italy)
Active substance
Glicopirronio
Manufacturer
NOVARTIS EUROPHARM LTD
Country
Italy (IT)
ATC code
R03BB06
ATC class
Glycopyrronium bromid
Defined daily dose
44 mcg, Inhal
Reimbursed
Yes
Source register
AIFA (Italy)
Last checked
September 28, 2026

Packs & prices · 1

1 priced
  • aic
    042306035
    "44 MCG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER (ALU/ALU)" 30X1 CAPSULA (DOSE UNITARIA) + 1 INALATORE
    EUR 24.96

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

213 interactions on record for glycopyrronium bromid.

Graded by severity as the source publishes them — 6 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check glycopyrronium bromid against other medicinesHow interaction checks work

Glycopyrronium bromid · interactions on record

213 records

  • 6 severe
  • 190 moderate
  • 17 minor

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe
  • TopiramatN02CX12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Glycopyrronium bromid in 11 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All glycopyrronium bromid products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • Austria · Rybrila
  • Germany · Rybrila
  • Spain · Axhidrox
  • Sweden · Glycopyrronium Cantabria

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AIFA (Italy). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/f7969b21-5978-44a6-8f85-68810ddc2f41
GET /v1/drugs/f7969b21-5978-44a6-8f85-68810ddc2f41?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pack": "\"44 MCG POLVERE PER INALAZIONE CAPSULA RIGIDA USO INALATORIO BLISTER (ALU/ALU)\" 30X1 CAPSULA (DOSE UNITARIA) + 1 INALATORE",
  "source": "aifa",
  "currency": "EUR",
  "substance": "Glicopirronio",
  "reference_pack": "30 UNITA' 44 MCG - USO RESPIRATORIO",
  "public_price_eur": 24.96,
  "ssn_reference_price_eur": 45.37
}
API referenceMCP serverPlans

See everything about glycopyrronium bromid.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console